Search Results - Schmidt-Hieber, Charlotte

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    P109: One‐Day Brentuximab‐Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma

    P109: One‐Day Brentuximab‐Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma by Moatti, Hannah, Laroque, Marie‐Céleste, Renaud, Loïc., Ravdan, Odonchimeg, Schmidt‐Hieber, Charlotte, Madelaine, Isabelle, Di Blasi, Roberta, Thieblemont, Catherine, Brice, Pauline

    Published in HemaSphere
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

    FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL by Dartigeas, Caroline, Slama, Borhane, Doyle, Margaret, Tapprich, Christoph, Albrecht, Claire, Dupuis, Sandrine, Wapenaar, Robert, Schmidt-Hieber, Charlotte, Leblond, Veronique

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: